Font Size

Search  
MSSNZ trademark with initials and carnation

Research Highlights 2007

 

Go direct to issue number:

 43  | 42  | 41  | 40 
 39  | 38  | 37  | 36  | 35  | 34  | 33  | 32  | 31 
 30  | 29  | 28  | 27  | 26  | 25  | 24  | 23  | 22 
 21  | 20  | 19  | 18  | 17  | 16  | 15  | 14  | 12 
 13  | 11  | 10  | 09  | 08  | 07  | 06  | 05  | 04 

 

Issue 43   as at 14 December 2007

1Combination therapy including antibiotics may be beneficial for MS 2MS and brain white matter 3Hep B vaccine exposure and risk of childhood MS 4Reasons for stopping interferon treatment 5Fatigue in MS

Issue 42   as at 7 December 2007

1MS drugs delay progression of disability in relapsing MS

Issue 41   as at 30 November 2007

1T-cell clones in MS 2Eye properties of those with MS examined 3Reliability of reported MS prevalence rates

Issue 40   as at 23 November 2007

1Sexual intimacy & MS 2Genetics & MS again 3Prevalence of MS in Northern Italy may defy latitude-related thinking about MS occurrence

Issue 39   as at 16 November 2007

1Relationship of short-term lesion recovery to progression and disability in MS
Top of Page

Issue 38   as at 12 November 2007

1Study finds evidence of Epstein-Barr virus in MS brain tissues 2Predicting cognitive impairment in MS 3Mitochondria in MS 4Depression is not directly associated with disease modifying drugs 5Parental transmission of MS
Top of Page

Issue 37   as at 2 November 2007

1Research Progress Reported at International ECTRIMS Meeting 2Eye scanning device detects MS nervous system damage 3Researchers report findings on antibody that stimulates myelin repair

Issue 36   as at 5 October 2007

1A new surgical means of treating tremor is MS 2Primary Progressive MS 3Cognitive tests and safety to drive in people with MS 4Genetic risk types for optic neuritis and MS 5Incidence of MS in the United Kingdom 6MS relapses analysed 7MS is not a sexually transmitted disease 8Stem cells transplants in MS and brain volume loss 9Neutralising antibodies with Interferon treatment
Top of Page

Issue 35   as at 28 September 2007

1New MRI technique to better diagnose MS 2Primary progressive MS and Copaxone© 3MS & the brain’s thalamus 4MS & vision tests 5MS & physical exercise 6Semaphorin 3A and 3F: key players in myelin repair 7Incidence of MS in Saskatchewan, Canada

Issue 34   as at 21 September 2007

1Parental smoking and the risk of MS 2Mitoxantone & MS 3Role of brain’s hippocampus in MS assessed 4Herpes virus and MS 5Cognitive-behavioural aspects of MS investigated
Top of Page

Issue 33   as at 14 September 2007

1Emerging oral therapies for MS 2Fingolimod reviewed 3New MRI technique for detecting lesions 4Associations between cervical cord grey matter damage and disability

Issue 32   as at 7 September 2007

1Drug proves effective for progressive MS 2Cellular marker for MS discovered

Issue 31   as at 31 August 2007

1Small Phase 2 Study of Daclizumab shows benefit alone and in combination with Interferon 2‘Designer oestrogen’ identified as potential MS drug 3Quality of information on the web about MS assessed 4MS in children 5New MRI finding sheds light on MS disease progression 6Omega-3 can help people with MS
Top of Page

Issue 30   as at 17 August 2007

1MS Vaccine appears safe 2Fingolimod effective in rats 3Treatment of tremor in MS 4Depression in MS 5Grey matter loss and cognitive function in MS 6Determinants of disability in MS 7Health status of those with MS in Canada

Issue 29   as at 10 August 2007

1Early treatment delays disability progression 2New MRI techniques used in MS evaluations 3MS & Parkinson's Disease compared 4Combination therapy in MS assessed 5Antibodies against light neurofilaments in MS 6New pathway for MS drug uncovered
Top of Page

Issue 28   as at 3 August 2007

1New genetic risk factors for MS identified

Issue 27   as at 27 July 2007

1Study finds early sun exposure associated with reduced risk of MS 2Quality of Life measures in MS 3Bone marrow transplant doesn’t avert MS 4Use of epilepsy treatment for severe MS 5Cannabinoids in MS treatment 6Peroxiredoxin V in MS lesions

Issue 26   as at 20 July 2007

1Internet-based cognitive testing in MS 2Using performance scales in disability assessment in MS 3Cerebrovascular reactivity in people with MS 4Mild MS and effects of exercise 5Pregnancy in MS after disease modifying therapy 6Depression in people with MS 7MS prevalence in eastern France 8Identifying which T cells drive the development of MS/EAE 9Imaging technique shows calcium ions may have role in MS

Issue 25   as at 13 July 2007

1Differences in MS between Canadian natives and the general population 2Cognitive dysfunctions associated with MS
Top of Page

Issue 24   as at 6 July 2007

1Parental transmission of MS 2MS during and after pregnancy 3Oligoclonal bands in MS 3MS is stronger in African Americans than in whites

Issue 23   as at 29 June 2007

1People who develop MS in childhood take longer to develop progressive disability 2Predicting short-term disability in MS 3Natalizumab for MS

Issue 22   as at 22 June 2007

1Predicting & delaying MS 2Autoimmune disease in families with MS 3Strong evidence for performing MRI after one year of treatment 4Two cases of brainstem lesions in MS and migraine

Issue 21   as at 15 June 2007

1Migraine in MS 2Neuromyelitis optica and MS 3Smoking and MS 4Herpes virus and types of MS 5Possible target of immune attack in MS and new therapeutic approach identified
Top of Page

Issue 20   as at 1 June 2007

1Oral treatments for MS: the story so far 2Financial impact of MS 3Newly identified gene may help protect people from developing MS

Issue 19   as at 25 May 2007

1Cognitive impairment in MS 2Course & progression of MS is age-dependent 3Treatment advances in MS

Issue 18   as at 18 May 2007

1Testosterone may help men with MS 2Combination therapies for MS 3Glucosamine-like supplement inhibits MS & Type 1 Diabetes 4MS associated with systemic sclerosis 5New concepts on progressive MS 6Oral agents for MS 7Prognosis of individual course of MS 8The role of dendritic cells in MS 9Demyelination in the forebrain
Top of Page

Issue 17   as at 11 May 2007

1Mitoxantrone in the news again 2Correlation between disability and deep grey matter measured on MRI 3Autoreactive antibodies and anti-interferon-beta antibodies in MS 4Self-reporting questionnaires in MS

Issue 16   as at 4 May 2007

1Reducing spasticity in MS 2Interferon-beta has greater effect in relapsing than in progressive MS 3Interferon beta-1a can slow progression of brain atrophy 4Stem cell transplantation fails to stop MS progression 5Difference between MS and Neuromyelitis optica 6Health, disability and life insurance experiences of working-age people with MS in the US 7Minocycline in MS
Top of Page

Issue 15   as at 27 April 2007

1Natalizumab reduces visual loss 2Paediatric MS 3Relationship between disability in MS, skin type, gender and ultraviolet radiation 4MS in Spain
Top of Page

Issue 14   as at 20 April 2007

1The cost of MS in Australia 2Use of magnetisation transfer MRI in MS 3Concepts & controversies about the cause of MS 4Natalizumab treatment for MS

Issue 13   as at 13 April 2007

1Cost effectiveness of MS treatments 2MS & MRI 3Fatigue in MS 4Effect of aerobic training in people with MS 5Saving myelin from microglia

Issue 12   as at 30 March 2007

1Clinical outcome measures in MS 2Glatiramer acetate (Copaxone®) in relapsing-remitting MS 3Childhood MS in Iran 4Interferon-beta 1a for the treatment of MS 5Cyclophosphamide in MS therapy
Top of Page

Issue 11   as at 23 March 2007

1Misdiagnosis of MS 2US Study suggests Vitamin D protects against MS 3Fun in the sunshine can be good for you!

Issue 10   as at 16 March 2007

1Cannabis-based drug trial reported some benefit for relieving spasticity in MS 2Age at onset of MS determines the occurrence of the progressive phase 3Palliative care in people with severe MS 4Experiences of people severely affected by MS 5Interferon-beta 1b in MS 6Grey and normal-appearing white matter in MS: an MRI perspective
Top of Page

Issue 9   as at 9 March 2007

1Use and impact of particular test scores in MS 2Literature review of relationship between MS and HLA 3Grey matter involvement in MS 4Current trends in MS – literature review

Issue 8   as at 2 March 2007

1A possible biomarker for MS 2Immediate and delayed MRI response after injection 3MS & Mitoxantrone 4EDSS and anxiety & depression in MS 5Tremor in MS 6Effect on MS of T-regulatory cell activity 7Costs and quality of life in MS 8Beneficial effect of cannabinoid compounds for the treatment of MS

Issue 7   as at 23 February 2007

1Regional variations of MS prevalence in French farmers 2Follow-up of benign MS at 20 years 3MS in a Dutch genetic isolated population 4Frequency of bladder, bowel or sexual dysfunction in MS 5Stem cell transplantation and MS 6Measuring cognitive impairment in MS 7MS & estrogen
Top of Page

Issue 6   as at 16 February 2007

1Parasite infection may benefit people with MS 2Cerebral atrophy and MS 3Deep grey matter perfusion in MS 4Demyelination and white matter changes in MS 5Interferon Gamma and MS 6MS incidence in North American natives 7MS prevalence in Colombia, South America 8Cognitive decline in people with MS

Issue 5   as at 9 February 2007

1Antibodies to myelin don't predict MS progression 2MS-associated retrovirus 3Hereditary factors and susceptibility to MS 4Measuring EDSS progression in MS 5Brain atrophy in MS 6Long-term emotional state of people with MS treated with interferon-beta 7The effect of disease modifying treatments in MS 8Myelin water imaging in MS
Top of Page

Issue 4   as at 2 February 2007

1Cannabis extract effective in the treatment of neuropathic pain 2Spasticity in MS and Savitex 3Caregiver burden in MS 4Association between parasite infection and immune responses in MS 5Role for estrogen in MS 6Family members with MS likely to share onset age, but not disease severity
Print this page
Read disclaimer